Literature DB >> 3499930

Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases.

U Dührsen1, W Augener, T Zwingers, G Brittinger.   

Abstract

The records of 637 patients with lymphoproliferative disorders and 346 patients with myeloproliferative disorders were retrospectively analysed for the presence of additional autoimmune derangements. The frequency of autoimmune perturbations in lymphoproliferative diseases (51 cases; 8.0%) was significantly higher than in myeloproliferative diseases (six cases; 1.7%; P less than 0.0001). Rheumatic disorders, autoallergic haematological manifestations and other organ-specific autoimmune derangements were responsible for about one third each of the observed disturbances. Autoimmune diseases which preceded the onset of malignancy, occurred in lymphoproliferative and myeloproliferative disorders with a comparable frequency without significant differences between individual subgroups of lymphoproliferative diseases. In contrast, autoimmune complications developing in the course of the neoplastic disease were significantly more frequent in lymphoproliferative (4.9%) than in myeloproliferative disorders (0.3%; P less than 0.0005). Here marked differences were observed between individual lymphoma entities, the rate of concomitant autoimmune derangements ranging from zero to over 15%. With the exception of centroblastic-centrocytic lymphoma which in no case was associated with secondary autoimmune complications, the proportion of patients with autoimmune perturbations increased with improving prognosis of the lymphoproliferative diseases. Possible pathogenetic mechanisms involved in the manifestation of autoimmune complications in malignant lymphomas are discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3499930     DOI: 10.1111/j.1365-2141.1987.tb02333.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature.

Authors:  Joe Puthenparambil; Klaus Lechner; Gabriela Kornek
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

Review 2.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 3.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 4.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 5.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

6.  Anti-erythropoietin receptor antibody-associated pure red cell aplasia accompanied by Coombs-negative autoimmune hemolytic anemia in a patient with T cell/histiocyte-rich large B cell lymphoma.

Authors:  Akihito Fujimi; Yusuke Kamihara; Yuji Kanisawa; Akari Hashimoto; Chisa Nakajima; Naotaka Hayasaka; Naoki Uemura; Toshinori Okuda; Shinya Minami; Satoshi Iyama; Koichi Takada; Tsutomu Sato; Akinori Hara; Yasunori Iwata; Kengo Furuichi; Takashi Wada; Junji Kato
Journal:  Int J Hematol       Date:  2014-08-06       Impact factor: 2.490

7.  Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.

Authors:  Kazuyo Nagashima; Hiroaki Tanaka; Yurie Nagai; Yasumasa Sugita
Journal:  BMJ Case Rep       Date:  2016-09-20

Review 8.  Targeting inflammatory pathways in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; Michael J Keating; Zeev Estrov
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-12       Impact factor: 6.312

9.  Fatal massive hemolysis caused by immunoglobulin M anti-c antibody in a patient with newly diagnosed B-cell acute lymphoblastic leukemia: a case report.

Authors:  Carlos Galvez; Abdulrahman Abutaleb; Wade T Iams; Paul F Lindholm; Hau C Kwaan
Journal:  Clin Case Rep       Date:  2018-04-17

10.  The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Simona Sica; Dimitar G Efremov
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.